Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 1/2014

01-01-2014 | ORPHAN DISEASES (B MANGER, SECTION EDITOR)

The Collagenopathies: Review of Clinical Phenotypes and Molecular Correlations

Authors: Rebekah Jobling, Rohan D’Souza, Naomi Baker, Irene Lara-Corrales, Roberto Mendoza-Londono, Lucie Dupuis, Ravi Savarirayan, L. Ala-Kokko, Peter Kannu

Published in: Current Rheumatology Reports | Issue 1/2014

Login to get access

Abstract

Genetic defects of collagen formation (the collagenopathies) affect almost every organ system and tissue in the body. They can be grouped by clinical phenotype, which usually correlates with the tissue distribution of the affected collagen subtype. Many of these conditions present in childhood; however, milder phenotypes presenting in adulthood are increasingly recognized. Many are difficult to differentiate clinically. Precise diagnosis by means of genetic testing assists in providing prognosis information, family counseling, and individualized treatment. This review provides an overview of the current range of clinical presentations associated with collagen defects, and the molecular mechanisms important to understanding how the results of genetic testing affect medical care.
Literature
1.
Carter EM, Raggio CL. Genetic and orthopedic aspects of collagen disorders. Curr Opin Pediatr. 2009;21:46–54.PubMedCrossRef
2.
Shaw LM, Olsen BR. FACIT collagens: diverse molecular bridges in extracellular matrices. Trends Biochem Sci. 1991;16:191–4.PubMedCrossRef
3.
Van Dijk FS, Pals G, Van Rijn RR, Nikkels PGJ, Cobben JM. Classification of osteogenesis imperfecta revisited. Eur J Med Genet. 2010;53:1–5.PubMedCrossRef
4.
5.
Sykes B, Ogilvie D, Wordsworth P, et al. Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2. Am J Hum Genet. 1990;46:293–307.PubMedCentralPubMed
6.
Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101–16.PubMedCrossRef
7.
Körkkö J, Ala-Kokko L, De Paepe A, et al. Analysis of the COL1A1 and COL1A2 genes by PCR amplification and scanning by conformation-sensitive gel electrophoresis identifies only COL1A1 mutations in 15 patients with osteogenesis imperfecta type I: identification of common sequences of null-allele mutations. Am J Hum Genet. 1998;62:98–110.PubMedCentralPubMedCrossRef
8.
9.
Willing MC, Deschenes SP, Slayton RL, Roberts EJ. Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains. Am J Hum Genet. 1996;59(4):799–809.PubMedCentralPubMed
10.
Slayton RL, Deschenes SP, Willing MC. Nonsense mutations in the COL1A1 gene preferentially reduce nuclear levels of mRNA but not hnRNA in osteogenesis imperfecta type I cell strains. Matrix Biol J Int Soc Matrix Biol. 2000;19:1–9.CrossRef
11.
Byers PH. Osteogenesis imperfecta: perspectives and opportunities. Curr Opin Pediatr. 2000;12:603–9.PubMedCrossRef
12.
Monti E, Mottes M, Fraschini P, et al. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010;6:367–81.PubMedCentralPubMed
13.
Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947–52.PubMedCrossRef
14.
Viora E, Sciarrone A, Bastonero S, et al. Osteogenesis imperfecta associated with increased nuchal translucency as a first ultrasound sign: report of another case. Ultrasound Obstet Gynecol. 2003;21(2):200–2.PubMedCrossRef
15.
van Dijk FS, Cobben JM, Kariminejad A, et al. Osteogenesis imperfecta: a review with clinical examples. Mol Syndromology. 2011;2(1):1–20.
16.
• van Dijk FS, Byers PH, Dalgleish R, et al. EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. Eur J Hum Genet. 2012;20(1):11–9. A useful resource for understanding the diagnostic process when faced with a patient with suspected OI, including non-collagen-related OI.PubMedCrossRef
17.
Cubert R, Cheng EY, Mack S, Pepin MG, Byers PH. Osteogenesis imperfecta: mode of delivery and neonatal outcome. Obstet Gynecol. 2001;97(1):66–9.PubMedCrossRef
18.
McAllion SJ, Paterson CR. Musculo-skeletal problems associated with pregnancy in women with osteogenesis imperfecta. J Obstet Gynaecol. 2002;22(2):169–72.PubMedCrossRef
19.
Sharma A, George L, Erskin K. Osteogenesis imperfecta in pregnancy: two case reports and review of literature. Obstet Gynecol Surv. 2001;56(9):563–6.PubMedCrossRef
20.
Edge G, Okafor B, Fennelly ME, Ransford AO. An unusual manifestation of bleeding diathesis in a patient with osteogenesis imperfecta. Eur J Anaesthesiol. 1997;14(2):215–9.PubMedCrossRef
21.
Scott D, Stiris G. Osteogenesis imperfecta tarda; a study of 3 families with special reference to scar formation. Acta Med Scand. 1953;145(4):237–57.PubMedCrossRef
22.
Carlson JW, Harlass FE. Management of osteogenesis imperfecta in pregnancy. A case report. J Reprod Med. 1993;38(3):228–32.PubMed
23.
Vogel TM, Ratner EF, Thomas Jr RC, Chitkara U. Pregnancy complicated by severe osteogenesis imperfecta: a report of two cases. Anesth Analg. 2002;94(5):1315–7.PubMedCrossRef
24.
• Kannu P, Bateman J, Savarirayan R. Clinical phenotypes associated with type II collagen mutations. J Paediatr Child Health. 2012;48:E38–43. This review provides a full description of the extremely variable phenotypes associated with type II collagen mutations. It expands on the information presented here.PubMedCrossRef
25.
Saldino RM. Lethal short-limbed dwarfism: achondrogenesis and thanatophoric dwarfism. Am J Roentgenol Radium Ther Nucl Med. 1971;112:185–97.PubMedCrossRef
26.
Dertinger S, Söeder S, Bösch H, Aigner T. Matrix composition of cartilaginous anlagen in achondrogenesis type II (Langer-Saldino). Front Biosci J Virtual Libr. 2005;10:446–53.CrossRef
27.
Faivre L, Le Merrer M, Douvier S, et al. Recurrence of achondrogenesis type II within the same family: evidence for germline mosaicism. Am J Med Genet A. 2004;126A:308–12.PubMedCrossRef
28.
Nishimura G, Nakashima E, Mabuchi A, et al. Identification of COL2A1 mutations in platyspondylic skeletal dysplasia, torrance type. J Med Genet. 2004;41:75–9.PubMedCrossRef
29.
Snead MP, Yates JR. Clinical and molecular genetics of stickler syndrome. J Med Genet. 1999;36:353–9.PubMed
30.
Sirko-Osadsa DA, Murray MA, Scott JA, et al. Stickler syndrome without eye involvement is caused by mutations in COL11A2, the gene encoding the alpha2(XI) chain of type XI collagen. J Pediatr. 1998;132:368–71.PubMedCrossRef
31.
• Robin NH, Moran RT, Warman M, Ala-Kokko L. Stickler syndrome. In: Pagon RA, Adam MP, Bird TD, et al. editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2013. 2000 June 9 [updated 2011 Nov 3]. <http://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK1302/​>. A complete and up-to-date review of diagnosis and management of Stickler syndrome.
32.
Roy DR. Spectrum of intra-articular findings of the acute and subacute painful hip with multiple epiphyseal dysplasia/spondyloepiphyseal dysplasia. J Pediatr Orthop B. 2011;20:284–6.PubMedCrossRef
33.
Gilbert-Barnes E, Langer Jr LO, Opitz JM, Laxova R, Sotelo-Arila C. Kniest dysplasia: radiologic, histopathological, and scanning electronmicroscopic findings. Am J Med Genet. 1996;63:34–45.PubMedCrossRef
34.
Wilkin DJ, Artz AS, South S, et al. Small deletions in the type II collagen triple helix produce Kniest dysplasia. Am J Med Genet. 1999;85:105–12.PubMedCrossRef
35.
Chan D, Jacenko O. Phenotypic and biochemical consequences of collagen X mutations in mice and humans. Matrix Biol. 1998;17:169–84.PubMedCrossRef
36.
Makitie O, Susic M, Ward L, Barclay C. Schmid type of metaphyseal chondrodysplasia and COL10A1 mutations—findings in 10 patients. Am J Med Genet. 2005;137(3):241–8.CrossRef
37.
Miyamoto Y, Matsuda T, Kitoh H, et al. A recurrent mutation in type II collagen gene causes Legg–Calvé–Perthes disease in a Japanese family. Hum Genet. 2007;121:625–9.PubMedCrossRef
38.
Liu Y-F, Chen WM, Lin YF, et al. Type II collagen gene variants and inherited osteonecrosis of the femoral head. N Engl J Med. 2005;352:2294–301.PubMedCrossRef
39.
Kannu P, Bateman JF, Randle S, et al. Premature arthritis is a distinct type II collagen phenotype. Arthritis Rheum. 2010;62:1421–30.PubMedCrossRef
40.
Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers–Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers–Danlos National Foundation (USA) and Ehlers–Danlos Support Group (UK). Am J Med Genet. 1998;77:31–7.PubMedCrossRef
41.
• Symoens S, Syx D, Malfait F, et al. Comprehensive molecular analysis demonstrates type V collagen mutations in over 90% of patients with classic EDS and allows to refine diagnostic criteria. Hum Mutat. 2012;33:1485–93. This paper established type V collagen mutations as the most important etiology of classic EDS. The prior estimate of cases of classic EDS caused by type V collagen mutations was approximately 50 %.PubMedCrossRef
42.
43.
Giunta C, Chambaz C, Pedemonte M, Scapolan S, Steinmann B. The arthrochalasia type of Ehlers–Danlos syndrome (EDS VIIA and VIIB): the diagnostic value of collagen fibril ultrastructure. Am J Med Genet A. 2008;146A:1341–6.PubMedCrossRef
44.
Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers–Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342:673–80.PubMedCrossRef
45.
Leistritz DF, Pepin MG, Schwarze U, Byers PH. COL3A1 haploinsufficiency results in a variety of Ehlers–Danlos syndrome type IV with delayed onset of complications and longer life expectancy. Genet Med Off J Am Coll Med Genet. 2011;13:717–22.
46.
Narcisi P, Richards AJ, Ferguson SD, Pope FM. A family with Ehlers–Danlos syndrome type III/articular hypermobility syndrome has a glycine 637 to serine substitution in type III collagen. Hum Mol Genet. 1994;3:1617–20.PubMedCrossRef
47.
Hausser I, Anton-Lamprecht I. Differential ultrastructural aberrations of collagen fibrils in Ehlers–Danlos syndrome types I–IV as a means of diagnostics and classification. Hum Genet. 1994;93:394–407.PubMedCrossRef
48.
Schwarze U, Hata R, McKusick VA, et al. Rare autosomal recessive cardiac valvular form of Ehlers–Danlos syndrome results from mutations in the COL1A2 gene that activate the nonsense-mediated RNA decay pathway. Am J Hum Genet. 2004;74:917–30.PubMedCentralPubMedCrossRef
49.
De Paepe A, Malfait F. The Ehlers–Danlos syndrome, a disorder with many faces. Clin Genet. 2012;82:1–11.PubMedCrossRef
50.
Bergqvist D, Björck M, Wanhainen A. Treatment of vascular Ehlers–Danlos syndrome: a systematic review. Ann Surg. 2013;258:257–61.PubMedCrossRef
51.
• Pepin MG, Byers PH. Ehlers–Danlos syndrome type IV. In: Pagon RA, Adam MP, Bird TD, et al. editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2013. 1999 Sep 02 [updated 2011 May 03] <http://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK1494/​>. A complete and up-to-date review of diagnosis and management of EDS vascular type.
52.
Ong K-T, Perdu J, De Backer J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers–Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010;376:1476–84.PubMedCrossRef
53.
Rombaut L, Malfait F, Cools A, De Paepe A, Calders P. Musculoskeletal complaints, physical activity and health-related quality of life among patients with the Ehlers–Danlos syndrome hypermobility type. Disabil Rehabil. 2010;32:1339–45.PubMedCrossRef
54.
Lind J, Wallenburg HC. Pregnancy and the Ehlers–Danlos syndrome: a retrospective study in a Dutch population. Acta Obstet Gynecol Scand. 2002;81(4):293–300.PubMedCrossRef
55.
Hammond R, Oligbo N. Ehlers Danlos Syndrome Type IV and pregnancy. Arch Gynecol Obstet. 2012;285(1):51–4.PubMedCrossRef
56.
Castori M, Morlino S, Dordoni C, et al. Gynecologic and obstetric implications of the joint hypermobility syndrome (a.k.a. Ehlers–Danlos syndrome hypermobility type) in 82 Italian patients. Am J Med Genet A. 2012;158A(9):2176–82.PubMedCrossRef
57.
Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers–Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342(10):673–80.PubMedCrossRef
58.
Erez Y, Ezra Y, Rojansky N. Ehlers–Danlos Type IV in pregnancy. A case report and a literature review. Fetal Diagn Ther. 2008;23(1):7–9.PubMedCrossRef
59.
60.
• Kuo DS, Labelle-Dumais C, Gould DB. COL4A1 and COL4A2 mutations and disease: insights into pathogenic mechanisms and potential therapeutic targets. Hum Mol Genet. 2012;21:R97–R110. An excellent in-depth review of current knowledge of phenotype and pathogenic mechanisms in COL4A1 and COL4A2-related disease.PubMedCrossRef
61.
Hudson BG, Reeders ST, Tryggvason K. Type IV: collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem. 1993;268:26033–6.PubMed
62.
Sipilä L, Ruotsalainen H, Sormunen R, et al. Secretion and assembly of type IV and VI collagens depend on glycosylation of hydroxylysines. J Biol Chem. 2007;282:33381–8.PubMedCrossRef
63.
Vanacore RM, Friedman DB, Ham A-JL, Sundaramoorthy M, Hudson BG. Identification of S-hydroxylysyl-methionine as the covalent cross-link of the noncollagenous (NC1) hexamer of the alpha1alpha1alpha2 collagen IV network: a role for the post-translational modification of lysine 211 to hydroxylysine 211 in hexamer assembly. J Biol Chem. 2005;280:29300–10.PubMedCrossRef
64.
Aguglia U, Gambardella A, Breedveld GJ, et al. Suggestive evidence for linkage to chromosome 13qter for autosomal dominant type 1 porencephaly. Neurology. 2004;62:1613–5.PubMedCrossRef
65.
Yoneda Y, Haginoya K, Arai H, et al. De novo and inherited mutations in COL4A2, encoding the type IV collagen α2 chain cause porencephaly. Am J Hum Genet. 2012;90:86–90.PubMedCentralPubMedCrossRef
66.
Van der Knaap MS, Smit LM, Barkhof F, et al. Neonatal porencephaly and adult stroke related to mutations in collagen IV A1. Ann Neurol. 2006;59:504–11.PubMedCrossRef
67.
Gould DB, Phalan FC, van Mil SE, et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med. 2006;354:1489–96.PubMedCrossRef
68.
Plaisier E, Gribouval O, Alamowitch S, et al. COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. N Engl J Med. 2007;357:2687–95.PubMedCrossRef
69.
Alamowitch S, Plaisier E, Favrole P, et al. Cerebrovascular disease related to COL4A1 mutations in HANAC syndrome. Neurology. 2009;73:1873–82.PubMedCrossRef
70.
Ninomiya Y, Kagawa M, Iyama K, et al. Differential expression of two basement membrane collagen genes, COL4A6 and COL4A5, demonstrated by immunofluorescence staining using peptide-specific monoclonal antibodies. J Cell Biol. 1995;130:1219–29.PubMedCrossRef
71.
Colville D, Savige J, Morfis M, et al. Ocular manifestations of autosomal recessive Alport syndrome. Ophthalmic Genet. 1997;18:119–28.PubMedCrossRef
72.
Kruegel J, Rubel D, Gross O. Alport syndrome—insights from basic and clinical research. Nat Rev Nephrol. 2013;9:170–8.PubMedCrossRef
73.
Bekheirnia MR, Reed B, Gregory MC, et al. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol. 2010;21:876–83.PubMedCrossRef
74.
Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history and genotype–phenotype correlations in girls and women belonging to 195 families: a ‘European Community Alport Syndrome Concerted Action’ study. J Am Soc Nephrol. 2003;14:2603–10.PubMedCrossRef
75.
Longo I, Porcedda P, Mari F, et al. COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int. 2002;61:1947–56.PubMedCrossRef
76.
Gross O, Licht C, Anders HJ, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 2012;81:494–501.PubMedCrossRef
77.
•• Temme J, Peters F, Lange K, et al. Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int. 2012;81:779–83. A large retrospective study demonstrating the nephroprotective effect of ACE inhibitors and angiotensin receptor blockers in patients with Alport syndrome.PubMedCrossRef
78.
Byrne MC, Budisavljevic MN, Fan Z, Self SE, Ploth DW. Renal transplant in patients with Alport’s syndrome. Am J Kidney Dis Off J Natl Kidney Found. 2002;39:769–75.CrossRef
79.
• Crovetto F, Moroni G, Zaina B, et al. Pregnancy in women with Alport syndrome. Int Urol Nephrol. 2013;45(4):1223–7. An excellent resource for the management of Alport syndrome in pregnancy.PubMedCrossRef
80.
Podymow T, August P, Akbari A. Management of renal disease in pregnancy. Obstet Gynecol Clin North Am. 2010;37(2):195–210.PubMedCrossRef
81.
Furthmayr H, Wiedemann H, Timpl R, Odermatt E, Engel J. Electron-microscopical approach to a structural model of intima collagen. Biochem J. 1983;211:303–11.PubMed
82.
Colombatti A, Mucignat MT, Bonaldo P. Secretion and matrix assembly of recombinant type VI collagen. J Biol Chem. 1995;270:13105–11.PubMedCrossRef
83.
Schessl J et al. Predominant fiber atrophy and fiber type disproportion in early ullrich disease. Muscle Nerve. 2008;38:1184–91.PubMedCrossRef
84.
Jöbsis GJ, Boers JM, Barth PG, de Visser M. Bethlem myopathy: a slowly progressive congenital muscular dystrophy with contractures. Brain J Neurol. 1999;122(Pt 4):649–55.CrossRef
85.
Merlini L, Martoni E, Grumati P, et al. Autosomal recessive myosclerosis myopathy is a collagen VI disorder. Neurology. 2008;71:1245–53.PubMedCrossRef
86.
Scacheri PC, Gillanders EM, Subramony SH, et al. Novel mutations in collagen VI genes: expansion of the Bethlem myopathy phenotype. Neurology. 2002;58:593–602.PubMedCrossRef
87.
Baker NL, Mörgelin M, Peat R. Dominant collagen VI mutations are a common cause of Ullrich congenital muscular dystrophy. Hum Mol Genet. 2005;14:279–93.PubMedCrossRef
88.
Okada M, Kawahara G, Noguchi S. Primary collagen VI deficiency is the second most common congenital muscular dystrophy in Japan. Neurology. 2007;69:1035–42.PubMedCrossRef
89.
90.
Camacho Vanegas O, Bertini E, Zhang RZ, et al. Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proc Natl Acad Sci U S A. 2001;98:7516–21.PubMedCentralPubMedCrossRef
91.
Demir E, Sabatelli P, Allamand V, et al. Mutations in COL6A3 cause severe and mild phenotypes of Ullrich congenital muscular dystrophy. Am J Hum Genet. 2002;70:1446–58.PubMedCentralPubMedCrossRef
92.
Ryynänen J, Sollberg S, Parente MG, et al. Type VII collagen gene expression by cultured human cells and in fetal skin. Abundant mRNA and protein levels in epidermal keratinocytes. J Clin Invest. 1992;89:163–8.PubMedCentralPubMedCrossRef
93.
Sakai LY, Keene DR, Morris NP, Burgeson RE. Type VII collagen is a major structural component of anchoring fibrils. J Cell Biol. 1986;103:1577–86.PubMedCrossRef
94.
Franzke C-W, Tasanen K, Schacke H, et al. Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. EMBO J. 2002;21:5026–35.PubMedCrossRef
95.
Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol. 2008;58(6):931–50.PubMedCrossRef
96.
Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol. 2009;61(3):367–84.PubMedCrossRef
97.
Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol. 2009;61(3):387–402.PubMedCrossRef
98.
Fine JD, Johnson LB, Weiner M, Li KP, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986–2006. Am Acad Dermatol. 2009;60(2):203–11.CrossRef
99.
Metadata
Title
The Collagenopathies: Review of Clinical Phenotypes and Molecular Correlations
Authors
Rebekah Jobling
Rohan D’Souza
Naomi Baker
Irene Lara-Corrales
Roberto Mendoza-Londono
Lucie Dupuis
Ravi Savarirayan
L. Ala-Kokko
Peter Kannu
Publication date
01-01-2014
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 1/2014
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-013-0394-3

Other articles of this Issue 1/2014

Current Rheumatology Reports 1/2014 Go to the issue

IMAGING (P CONAGHAN, SECTION EDITOR)

Insights into Rheumatoid Arthritis from Use of MRI

CHRONIC PAIN (R STAUD, SECTION EDITOR)

Effects of Obesity on Function and Quality of Life in Chronic Pain Conditions

CHRONIC PAIN (R STAUD, SECTION EDITOR)

Myofascial Trigger Points: Peripheral or Central Phenomenon?

CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

Mechanisms of Spontaneous Resolution of Acute Gouty Inflammation

ORPHAN DISEASES (B MANGER, SECTION EDITOR)

HFE-Related Hemochromatosis: An Update for the Rheumatologist

IMAGING (P CONAGHAN, SECTION EDITOR)

Clinical and Translational Potential of MRI Evaluation in Knee Osteoarthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits